Skip to content
Therapy But Better – Lifestyle
Author:
Liquidia Technologies, Inc.
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
October 13, 2026
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
September 30, 2026
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud’s Phenomenon Associated with Systemic Sclerosis
September 3, 2026
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
September 2, 2026
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
September 1, 2026
Liquidia Corporation Reports Second Quarter 2026 Financial Results
August 12, 2026
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
July 29, 2026
Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions
June 11, 2026
Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index
June 8, 2026
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
May 27, 2026
1
2
Next Page
→